Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (새로운 창 열기)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Source‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indexed‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (새로운 창 열기)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (새로운 창 열기)

Banan M.

Source‎: Ann Hematol 2013;92(3):289-99.

Indexed‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (새로운 창 열기)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (새로운 창 열기)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Source‎: Transfusion 2007;47(10):1830-6.

Indexed‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (새로운 창 열기)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (새로운 창 열기)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Source‎: Blood 1996;87(3):887-92.

Indexed‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (새로운 창 열기)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (새로운 창 열기)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Source‎: Iran J Blood Cancer 2009;1(4):147-50.

Indexed‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (새로운 창 열기)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (새로운 창 열기)

Karimi M, Cohan N, Pishdad P.

Source‎: Hematology 2015;20(1):53-7.

Indexed‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (새로운 창 열기)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (새로운 창 열기)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Source‎: Int J Hematol 2012;95(1):51-6.

Indexed‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (새로운 창 열기)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (새로운 창 열기)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Source‎: Hemoglobin 2014;38(2):115-8.

Indexed‎: PubMed 24471558

DOI‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (새로운 창 열기)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (새로운 창 열기)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Source‎: Blood 2013;121(12):2199-212.

Indexed‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (새로운 창 열기)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (새로운 창 열기)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Source‎: Sci Rep. 2022;12(1):2752.

Indexed‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (새로운 창 열기)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (새로운 창 열기)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Source‎: Haematologica 2004;89(10):1172-8.

Indexed‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (새로운 창 열기)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (새로운 창 열기)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Source‎: Arch Iran Med 2009;12(3):295-7.

Indexed‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (새로운 창 열기)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (새로운 창 열기)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Source‎: Eur J Haematol 1996;56(5):326-8.

Indexed‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (새로운 창 열기)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (새로운 창 열기)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Source‎: J Matern Fetal Med 1999;8(1):1-7.

Indexed‎: PubMed 10052837

DOI‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (새로운 창 열기)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (새로운 창 열기)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Source‎: Acta Haematol 2004;111(4):189-95.

Indexed‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (새로운 창 열기)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (새로운 창 열기)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Source‎: Ann Hematol 2001;80(8):492-5.

Indexed‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (새로운 창 열기)

Fetal globin induction--can it cure beta thalassemia? (새로운 창 열기)

Perrine SP.

Source‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Indexed‎: PubMed 16304357

DOI‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (새로운 창 열기)